That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19
Author:
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Microbiology (medical)
Link
https://link.springer.com/content/pdf/10.1007/s40121-020-00318-1.pdf
Reference33 articles.
1. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–71.
2. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature communications. 2020;11(1):222.
3. Lo MK, Jordan R, Arvey A, et al. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci Rep. 2017;7:43395.
4. Brown AJ, Won JJ, Graham RL, et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antivir Res. 2019;169:104541.
5. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017. https://doi.org/10.1126/scitranslmed.aal3653.
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Using Natural Language Processing for Context Identification in COVID-19 Literature;Advances in Bioinformatics and Computational Biology;2023
2. Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response;Journal of Clinical Investigation;2022-06-15
3. Contribution of endogenous and exogenous antibodies to clearance of SARS-CoV-2 during convalescent plasma therapy;2021-12-11
4. Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now?;Current Infectious Disease Reports;2021-12
5. Optimal Timing of Remdesivir Initiation in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Administered With Dexamethasone;Clinical Infectious Diseases;2021-08-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3